Cellceutix’s potential breakthrough in cancer research

Cellceutix (OTCBB:CTIX) of Beverly, Mass. believes it has found the Holy Grail in cancer research: a compound that activates a tumor suppressor protein known as p53, long regarded as possibly holding the key to future cancer therapies. “Our Kevetrin drug reactivates p53 to its normal function of dictating whether to fix the cell or kill [...]

CytoSorbents encouraged by market reception of CytoSorb

CytoSorbents (OTCBB: CTSO), which two months ago began a controlled market release for CytoSorb, its therapy to reduce cytokine storm in septic shock, is very encouraged by the market reception so far, CEO Dr. Phillip Chan said in the third quarter report. “The response at both the German Sepsis Society Congress and the European Society [...]

Transition stops development of diabetes drug

A clinical study of Transition Therapeutics’ (TSX:TTH; NASDAQ:TTHI) gastrin analogue TT-223 in combination with an Eli Lilly (NYSE: LLY) GLP-1 analogue in patients with Type 2 diabetes did not meet its efficacy endpoints and there will be no further development of TT-223. “While TT-223 had shown efficacy through development, these results indicate that it does [...]

YM reshuffles the Cytopia deck

YM BioSciences (AMEX:YMI; TSX:YM) got more than it bargained for with its recent acquisition of Australia’s Cytopia. “When we were buying the company, our sole interest was in CYT997, Cytopia’s lead vascular disrupting agent (VDA),” CEO David Allan told biotuesdays.com in an exclusive interview.  VDAs, which can disrupt the blood flow that feed tumours, became [...]

Transition buys rights to a series of preclinical diabetes assets from Lilly

Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has expanded its existing relationship with Eli Lilly (NYSE: LLY) by acquiring rights to a series of preclinical diabetes compounds from Lilly under a new licensing and collaboration agreement. Under the accord, Transition will pay Lilly $1 million (U.S.) and Lilly will retain an option to reacquire rights to the compounds [...]